Pharmaceutical administration systems containing a mixture of immunomodulators
First Claim
1. A pharmaceutical administration system consisting of(a) a water soluble muramylpeptide,(b) gamma-interferon,(c) a phospholipid of the formula ##STR7## wherein n is one, two or three, R1 and R2 independently of each other represent alkyl, alkenyl or acyl each having 10-20 carbon atoms, and Y.sup.⊕
- is the cation of a pharmaceutically acceptable base,(d) a phospholipid of the formula ##STR8## wherein n is two, three or four, R1 and R2 are defined as above and R3, R4 and R5 represent hydrogen or C1 -C4 -alkyl, and, optionally, a pharmaceutically acceptable carrier solution buffered to pH 7.0-7.8, and, optionally a pharmaceutically acceptable carrier in solid form.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to pharmaceutical administration systems containing phosphatidylserine and phosphatidylcholine or phosphatidylethanolamine derivatives in the form of liposomes which encapsulate water soluble muramyldipeptide derivatives in combination with gamma-interferon. The liposomes are prepared by conventional dispersion methods. The pharmaceutical administration systems when applied in the form of liposomes are especially useful in the cancer chemotherapy for combating metastatic tumor cells.
143 Citations
8 Claims
-
1. A pharmaceutical administration system consisting of
(a) a water soluble muramylpeptide, (b) gamma-interferon, (c) a phospholipid of the formula ##STR7## wherein n is one, two or three, R1 and R2 independently of each other represent alkyl, alkenyl or acyl each having 10-20 carbon atoms, and Y.sup.⊕ - is the cation of a pharmaceutically acceptable base,
(d) a phospholipid of the formula ##STR8## wherein n is two, three or four, R1 and R2 are defined as above and R3, R4 and R5 represent hydrogen or C1 -C4 -alkyl, and, optionally, a pharmaceutically acceptable carrier solution buffered to pH 7.0-7.8, and, optionally a pharmaceutically acceptable carrier in solid form. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
- is the cation of a pharmaceutically acceptable base,
Specification